Buy, hold, sell: Clarity Pharmaceuticals, New Hope, and Orica shares

Brokers have been busy looking over a number of ASX shares this week.

Let’s see what they are saying about the three named below, which have released updates in recent days. Here’s what you need to know:

Clarity Pharmaceuticals Ltd (ASX: CU6)

Bell Potter has been pleased with recent study data relating to this radiopharmaceutical company’s 64Cu-SAR-bis-PSMA PET product. It highlights that it is significantly outperforming Ga-PSMA-11 PET in the detection of biochemical recurrence in men with very low PSA levels.

As a result, the broker has reaffirmed its speculative buy rating and $6.40 price target on its shares. It said:

The stage is now set for a readout from the approval study for 64Cu-SAR-bisPSMA (AMPLIFY) which has now ceased accepting new patient consents and is practically fully enrolled (n=220). The Co-PSMA data along with data from COBRA and anticipated findings from AMPLIFY will form the basis of submission of a new drug application to be submitted to the FDA.

CU6 has three fast track designations for the SAR-bisPSMA agent which includes patients with BCR of prostate cancer following definitive therapy. The company is well funded with cash in excess of $226m at 31 Dec 2025.

New Hope Corporation Ltd (ASX: NHC)

This coal miner disappointed analysts at Morgans with its half-year results. The broker highlights that its net profits were much softer than expected.

In light of this, the broker has retained its hold rating with a $5.00 price target. It said:

Overall result missed expectations, with underlying NPAT of A$54m materially below MorgansF (A$63m) and Visible Alpha consensus (A$78m), despite EBITDA of A$215m coming in line with expectations. NHC declared a fully franked 10c dividend, beating MorgansF (8c) and consensus (6c) estimates.

With an increasing production profile and material upside potential in coal prices, NHCs outlook remains positive. We maintain a HOLD rating with a target price of A$5.00ps.

Orica Ltd (ASX: ORI)

Morgans was pleased with this commercial explosives and blasting systems company’s trading update.

It was also pleased to see its CF Industries litigation settled and the strengthening of its US operations with an acquisition.

This has seen Morgans reiterate its buy rating with an improved price target of $25.35. It said:

ORI’s trading update was slightly stronger than we expected. It also announced the settlement of its litigation with CF Industries and the acquisition of its US explosives JV partner, Nelson Brothers, strengthening its US operations. Higher AUD and Indonesia’s coal production quotas have seen us make minor revisions to our FY26 forecasts but the acquisition has upgraded FY27/28.

With leverage to attractive industry fundamentals, market leading positions, solid earnings growth, proven management team and strong balance sheet, we reiterate our BUY rating with a new price target of A$25.35.

The post Buy, hold, sell: Clarity Pharmaceuticals, New Hope, and Orica shares appeared first on The Motley Fool Australia.

More reading

• Exciting clinical news for this ASX healthcare stock earns it a buy recommendation 
• What is this broker saying about New Hope Group shares?
• 5 things to watch on the ASX 200 on Wednesday
• Why the New Hope share price is sliding today as coal debate heats up
• Why New Hope, Pepper Money, Pro Medicus, and Reece shares are falling today

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.